Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
25 nov. 2024 09h32 HE
|
Immix Biopharma, Inc.
75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS...
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
02 oct. 2024 09h32 HE
|
Immix Biopharma, Inc.
Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete...
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
19 sept. 2024 09h31 HE
|
Immix Biopharma, Inc.
Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL...
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
28 août 2024 09h32 HE
|
Immix Biopharma, Inc.
New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health Lead site Memorial Sloan Kettering Cancer...
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
25 juil. 2024 21h31 HE
|
Immix Biopharma, Inc.
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
08 juil. 2024 09h31 HE
|
Immix Biopharma, Inc.
Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS...
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
17 juin 2024 09h35 HE
|
Immix Biopharma, Inc.
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in...
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
10 mai 2024 09h35 HE
|
Immix Biopharma, Inc.
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to...
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
29 avr. 2024 09h39 HE
|
Immix Biopharma, Inc.
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU...
Immix Biopharma on Track to Dose NXC-201 Patients in United States
18 avr. 2024 09h32 HE
|
Immix Biopharma, Inc.
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S....